Rosacea — a chronic inflammatory skin condition affecting predominantly fair-skinned adults over 30 — is both one of the most common dermatological diagnoses and one of the most frequently undertreated. Approximately 16 million Americans have rosacea, but many go without diagnosis for years, attributing their persistent facial redness to "sensitive skin" or "blushing." The National Rosacea Society's consensus classification (updated 2017) defines four primary phenotypic subtypes with distinct treatment implications — not all rosacea responds to the same therapeutic approach. Our skin care catalog includes clinical products appropriate for rosacea-prone skin management.
Clinical Subtypes and Key Phenotypes
ETR (Erythematotelangiectatic rosacea): persistent central facial erythema, visible telangiectasias (broken capillaries), flushing — treatment centers on trigger avoidance, photoprotection, and for telangiectasias, vascular laser (pulsed dye laser, IPL) rather than topicals. PPR (Papulopustular rosacea): acneiform papules and pustules without comedones on background of redness — most responsive to topical and systemic anti-inflammatory therapy. Phymatous rosacea: rhinophyma (bulbous nasal enlargement) and skin thickening — responds to isotretinoin or surgical intervention, not topical therapy. Ocular rosacea: lid margin inflammation, chalazia, chronic conjunctivitis — systemic tetracyclines and warm compresses with lid hygiene are primary treatments, ophthalmology co-management recommended.
Evidence-Based Topical Treatments
Metronidazole 0.75–1% gel or cream: first-line for PPR rosacea with the longest evidence base — anti-inflammatory activity through reactive oxygen species scavenging reduces papulopustular lesions in 70–80% of patients. Azelaic acid 15–20%: particularly effective for both papulopustular lesions and dyspigmentation accompanying rosacea; superior to metronidazole in some trials, though more irritating initially. Ivermectin 1% cream (Soolantra): anti-parasitic targeting Demodex folliculorum mites (present in elevated numbers in rosacea skin), with anti-inflammatory activity — superior to metronidazole in large RCTs and particularly effective for Demodex-associated rosacea. Brimonidine 0.33% gel (Mirvaso): α-adrenergic agonist producing vasoconstriction for acute erythema reduction — tachyphylaxis and rebound flushing limit long-term utility.
Skincare Routine for Rosacea
The rosacea skincare routine prioritizes barrier support and trigger avoidance over active treatment: (1) Gentle syndet cleanser at pH 5–6; (2) Minimal-ingredient moisturizer with ceramides and niacinamide — no fragrance, no alcohol, no witch hazel; (3) Mineral SPF 30+ sunscreen (zinc oxide preferred — non-irritating, broad UVA protection); (4) Prescribed topical treatment; (5) Color-correcting green-tinted primer or foundation (cosmetic camouflage) for social occasions. Trigger avoidance individualization: sun exposure, heat, alcohol, spicy food, exercise, certain skincare ingredients (fragrances, alcohol, AHAs at high concentrations). Clinical skin care products appropriate for rosacea are available in our skin care section.
